EQL Pharma: New financial targets for the period 2024/25 - 2028/29

• Our target is to increase sales at an annual growth rate of 30% (CAGR), starting with the full year 2024/25 and ending the full year 2028/29.
  • Growth will mainly be organic
  • In connection with any acquisitions, the primary sources of funding will be existing cash alongside potential new debt
  • Target to reduce net leverage (net debt/pro-forma adjusted EBITDA) to below 2.5x. Temporary deviations above this level may occur in connection with strategic investments or acquisitions, but we do not intend to exceed 4.0x

• The EBITDA margin target for the period is 25%
  • Towards the end of the period, the target is to stabilize the EBITDA margin above 25%
  • The margin may temporarily be slightly lower than 25% in the middle of the period as a consequence of the margin profile for certain planned launches
  • Under the five-year plan, revenue growth will be prioritized over higher EBITDA margin to maximize long-term shareholder value taking into consideration a maintained healthy margin

The new financial targets will be presented in more detail today 7 March at the company's Capital Markets Day at Carnegie's premises in Stockholm. The full presentation from the Capital Markets Day will be available on EQL's website.